Author | Jill Wechsler

Officials struggle to maintain the credibility of its drug regulatory process after accusations of intentionally delaying COVID-19 vaccine testing for political reasons.

Should therapies and vaccines be cheap or free in a pandemic and would that really dry up innovation?

Public health authorities and the biomedical research community are seeking new strategies to address global health threats, writes Jill Wechsler.

The agency hopes to better use global resources and avoid duplicate inspections of foreign facilities.